Innovent Biologics Inc is an investment holding company mainly engaged in the discovery, development, manufacturing, and commercialization of medicines. The Company provides medicines for the treatment of cancer, cardiovascular and metabolism (CVM), autoimmune, eye and other diseases. The Companyâs product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), and others.

Employees

6,190

Sector

Pharmaceuticals

Calendar

03-31 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
11/12/25	83.65 $	+0.18%	8,646,635
10/12/25	83.50 $	-1.07%	10,285,260
09/12/25	84.40 $	-1.40%	20,002,920
08/12/25	85.60 $	-6.96%	52,658,030
05/12/25	92.00 $	-1.66%	33,885,830

Delayed Quote Hong Kong S.E., December 11, 2025 at 08:08 am

More quotes

Income Statement and Estimates

More financial data

Analysis / Opinion

Innovent Reports Strong Start for Obesity Drug

August 28, 2025 at 10:11 am

More Strategies

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

75.80CNY

Average target price

99.91CNY

Spread / Average Target

+31.82%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. Other stock markets 08:08:03 11/12/2025 GMT			5-day change	1st Jan Change
83.65 ^HKD	+0.18%		-10.58%	+128.55%

12-10	Innovent Biologics, Inc. Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody	CI
12-09	Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%	CI

Capitalization	130B 143B 18.39B 15.79B 14.77B 13.79B 25.45B 1,653B 27.69B 171B 66.71B 783B 69.01B 67.54B 2,875B	P/E ratio 2025 *	77.1x	P/E ratio 2026 *	42.4x
Enterprise value	120B 132B 17.02B 14.61B 13.67B 12.77B 23.56B 1,530B 25.63B 158B 61.75B 725B 63.87B 62.52B 2,661B	EV / Sales 2025 *	9.19x	EV / Sales 2026 *	6.87x
Free-Float	93.21%	Yield 2025 *	-	Yield 2026 *	0.02%

12-10	Innovent Biologics, Inc. Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody	CI
12-09	Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%	CI
12-09	Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP	CI
12-09	Ascentage Pharma Group International Presents Updated Data for Ascentage Pharma?S Olverembatinib in Second-Line Cml-Cp Showing Encouraging Potential for Early-Line Treatment	CI
12-09	Innovent Announces PECONDLE (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis	CI
12-08	Eli Lilly's Mounjaro enters China's insurance system – putting pressure on competitors	FW
12-08	Seven Innovent Biologics Drugs Included in China's Reimbursement Drug List; Shares Plunge 7%	MT
12-08	Innovent Biologics, Inc. Announces Initial Results of the First-In-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma	CI
12-07	Innovent Biologics, Inc.(SEHK:1801) added to Hang Seng China Enterprises Index	CI
12-07	Innovent Biologics, Inc.(SEHK:1801) added to Hang Seng Index	CI
12-07	Innovent Biologics, Inc. Announces Inclusion of Seven Innovative Drugs Including TYVYT New Indication and Sycume in China's National Reimbursement Drug List	CI
12-05	Nikkei Falls Amid Caution Ahead of U.S. Inflation Data, Bond Yields Surge	MT
12-05	Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies	CI

08-28	Nomura Adjusts Innovent Biologics' Price Target to HK$105.08 From HK$89.80, Keeps at Buy	MT
07-16	Macquarie Upgrades Innovent Biologics to Neutral from Underperform; Price Target is HK$75	MT
06-30	Nomura Adjusts Innovent Biologics' Price Target to HK$89.80 From HK$54.60, Keeps at Buy	MT
06-27	Innovent Biologics, Inc. Receives Approval by the National Medical Products Administration of China for Chronic Weight Management in Chinese Adults	CI
02-18	Nomura Adjusts Innovent Biologics' Price Target to HK$54.60 From HK$58.09, Keeps at Buy	MT

Innovent Biologics, Inc. Share Price

Equities

1801

KYG4818G1010

Pharmaceuticals

Valuation: Innovent Biologics, Inc.

Chart: Innovent Biologics, Inc.

Latest news: Innovent Biologics, Inc.

Last Transcript: Innovent Biologics, Inc.

Analysts' recommendations: Innovent Biologics, Inc.

Press Releases: Innovent Biologics, Inc.

News in other languages: Innovent Biologics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Innovent Biologics, Inc.

ETFs: Innovent Biologics, Inc.

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysis / Opinion

Analysts' Consensus

Quarterly revenue - Rate of surprise

12-08	ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma	PR
12-05	Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies	PR
11-25	Mazdutide 9mg Supplementary Application Accepted for Review by China's NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population	PR
11-24	Innovent Biologics Enters Hang Seng Index and Two Other Major Indices; Global Capital Markets Recognize Leading Innovator's Value	PR
11-20	Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints	PR

07-01	Ypsomed erhält Auftrag in China zur Verabreichung einer Adipositas-Behandlung
19/01/23	La actualización de la Lista Nacional de Medicamentos Reembolsables de China cumple las expectativas -- Market Talk
05/08/22	Les valeurs à suivre aujourd'hui à la Bourse de Paris Vendredi 5 août 2022
05/08/22	Sanofi : collaboration avec Innovent Biologics en Chine
05/08/22	Le CAC 40 attendu en légère hausse avant l'emploi américain

1 day	+0.18%
1 week	-10.58%
Current month	-11.11%
1 month	-1.88%
3 months	-13.85%
6 months	+4.63%
Current year	+128.55%

1 week	82.65	94.85
1 month	82.65	99
Current year	28.65	109.1
1 year	28.65	109.1
3 years	27.3	109.1
5 years	18.06	109.1
10 years	14	109.1

Manager	Title	Age	Since
De Chao Yu CEO	Chief Executive Officer	61	27/04/2011
Fei You DFI	Director of Finance/CFO	46	04/02/2024
Ghang Shou Gao CTO	Chief Tech/Sci/R&D Officer	-	31/10/2020

Director	Title	Age	Since
De Chao Yu CHM	Chairman	61	27/04/2011
Charles Cooney BRD	Director/Board Member	80	17/10/2015
Hao Xi Ede BRD	Director/Board Member	66	03/06/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
INNOVENT BIOLOGICS, INC.	+0.18%	-10.58%	+118.98%	+161.41%	18.39B
REGENERON PHARMACEUTICALS, INC.	+4.86%	+0.35%	-6.72%	-3.18%	74.51B
CSL LIMITED	-1.55%	-3.66%	-36.05%	-40.04%	58.22B
UCB	-0.99%	-0.04%	+33.26%	+232.22%	53.6B
SAMSUNG BIOLOGICS CO.,LTD.	+0.30%	+66.50%	+66.50%	+66.50%	52.43B
BIOGEN INC.	+0.97%	-1.77%	+13.58%	-37.78%	26.05B
INCYTE CORPORATION	+0.01%	-6.24%	+31.31%	+15.58%	18.68B
ALTEOGEN INC.	-0.11%	-12.55%	+43.55%	+1,012.06%	16.61B
INTRA-CELLULAR THERAPIES, INC.	-0.04%	-.--%	+58.67%	+154.72%	14.02B
BRIDGEBIO PHARMA, INC.	+1.44%	-1.96%	+150.34%	+717.77%	14.01B
Average	+0.51%	-3.10%	+47.34%	+227.93%	34.65B
Weighted average by Cap.	+0.81%	-1.57%	+27.27%	+128.92%

	2025 *	2026 *
Net sales	13.09B 14.42B 1.85B 1.59B 1.49B 1.39B 2.56B 167B 2.79B 17.25B 6.72B 78.95B 6.95B 6.81B 290B	17.17B 18.92B 2.43B 2.09B 1.95B 1.82B 3.36B 219B 3.66B 22.63B 8.82B 104B 9.12B 8.93B 380B
Net income	1.68B 1.85B 237M 204M 191M 178M 328M 21.33B 357M 2.21B 861M 10.11B 890M 872M 37.1B	3.07B 3.39B 435M 373M 349M 326M 602M 39.1B 655M 4.05B 1.58B 18.53B 1.63B 1.6B 68.02B
Net Debt	-9.67B -10.66B -1.37B -1.18B -1.1B -1.03B -1.9B -123B -2.06B -12.75B -4.97B -58.34B -5.14B -5.03B -214B	-11.92B -13.13B -1.69B -1.45B -1.36B -1.27B -2.34B -152B -2.54B -15.71B -6.12B -71.9B -6.33B -6.2B -264B